Green leaf pharmaceutical ansofasin reprieve tablet (LY03005) has been submitted for clinical trials in Japan
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, the http://Group of Green leafPharmaceutical
s announced that its new compound for the treatment of depression, the Antufaxin Reprieve (LY03005), has submitted a clinicaltrial(http://application in Japan, which is about to begin clinicalLY03005 has also entered Phase III clinical in China and entered a critical trial phase in the United States, where research and development is progressing smoothlyabout LY03005
LY03005 is one of the heavy-weightnew drug(http://of Green leaf pharmaceuticals in the field of central nerves, based on the Group's new compound platformIt is an exclusive hydrochloric acid Anshufasinproduct (http:// (a 5-serotonin-norepinephrine-dopamine triple-reuptake inhibitor (SNDRI)) prepared in the form of a slow release tablet Greenleaf Pharmaceuticals plans to register and market the Drug (http:// in the United States, China, Japan, Europe and other countries and regions Green leaf pharmaceuticals have a patented (http:// of covering the chemical composition, crystal morphology and preparation of slow release tablets Patents for chemical composition and crystal form have been obtained in China, the United States, Europe, Japan and Korea
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
